BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tepmetko (Tepotinib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tepmetko (Tepotinib)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT02925234-2033@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Tepmetko (Tepotinib): Phase 2 readout est. (NCT02925234)
DESCRIPTION:Tepmetko (Tepotinib)\, phase 2.\nStudy: The Drug Rediscovery Pr
 otocol (DRUP Trial)\nEstimated primary completion: September 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/tepotinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/tepotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06083857-2033@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tepmetko (Tepotinib): Phase 1/2 readout est. (NCT06083857)
DESCRIPTION:Tepmetko (Tepotinib)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non
 -small Cell Lung Cancer\nEstimated primary completion: 31 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/tepotinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06083857
URL:https://assetmemo.bio/drug/tepotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05782361-2033@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20280308
DTEND;VALUE=DATE:20280309
SUMMARY:Tepmetko (Tepotinib): Phase 1 readout est. (NCT05782361)
DESCRIPTION:Tepmetko (Tepotinib)\, phase 1\, Non-Small Cell Lung Cancer.\nS
 tudy: POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC\nEstim
 ated primary completion: 8 March 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/tepotinib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05782361
URL:https://assetmemo.bio/drug/tepotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06908993-2033@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20280315
DTEND;VALUE=DATE:20280316
SUMMARY:Tepmetko (Tepotinib): Phase 3 readout est. (NCT06908993)
DESCRIPTION:Tepmetko (Tepotinib)\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 1
 4 Mutated Non-Small Cell Lung Cancer Previously Treated\nEstimated primary
  completion: 15 March 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/tepotinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06908993
URL:https://assetmemo.bio/drug/tepotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619339-2033@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Tepmetko (Tepotinib): Phase 1 readout est. (NCT07619339)
DESCRIPTION:Tepmetko (Tepotinib)\, phase 1\, Non-Small Cell Lung Cancer.\nS
 tudy: A Study of Tepotinib and Ivonescimab in People With Non-Small Cell L
 ung Cancer\nEstimated primary completion: May 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/tepotinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07619339
URL:https://assetmemo.bio/drug/tepotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06106802-2033@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Tepmetko (Tepotinib): Phase 2 readout est. (NCT06106802)
DESCRIPTION:Tepmetko (Tepotinib)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or
  Amplified Who Progressed After Lazertinib Treatment\nEstimated primary co
 mpletion: 30 September 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/tepotinib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06106802
URL:https://assetmemo.bio/drug/tepotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05159245-2033@assetmemo.bio
DTSTAMP:20261121T004030Z
DTSTART;VALUE=DATE:20311125
DTEND;VALUE=DATE:20311126
SUMMARY:Tepmetko (Tepotinib): Phase 2 readout est. (NCT05159245)
DESCRIPTION:Tepmetko (Tepotinib)\, phase 2.\nStudy: The Finnish National St
 udy to Facilitate Patient Access to Targeted Anti-cancer Drugs\nEstimated 
 primary completion: 25 November 2031. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/tepotinib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05159245
URL:https://assetmemo.bio/drug/tepotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
